Mahyar Abidi

Director Of Analytics / Enterprise Architect at CinnaGen

Mahyar Abidi is an accomplished professional with extensive experience in analytics and business intelligence. Currently serving as the Director of Analytics and Enterprise Architect at CinnaGen since October 2015, Mahyar is responsible for guiding the integration and management of data analytics in alignment with business objectives. Previous roles include Senior Manager of Business Analytics at CinnaGen, where Mahyar led data-driven analysis to shape business strategies, and positions at System Group as Sales Manager and Business Intelligence Consultant, as well as Business Intelligence Analyst. Mahyar's early career includes serving as a Human Resource Information Systems Analyst at the University of Tehran and as a Teaching Assistant. Academic qualifications include a Master’s Degree in Industrial Management from the University of Tehran, an Executive MBA from Sharif University of Technology, and a Bachelor’s Degree in Industrial Engineering from Islamic Azad University.

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


CinnaGen

CinnaGen Co. has founded in 1994 with the goal of manufacturing High-Tech products in biotechnology and related fields. Since its start of operations with 4 scientists, CinnaGen has grown to become the biggest Biopharma manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products for covering regional market. Enzymes, molecular biology reagents and PCR kits are the first products and then CinnaGen use its proprietary set of technologies to endow Monoclonal Antibodies for blood group typing. The next important step for CinnaGen was the entry to the therapeutic recombinant protein area. Today the company prides itself in its innovative skills meeting today’s challenges. We focus our efforts on developing the biogenerics candidates in the areas of immunological diseases and oncology as well as providing contract research development services. The company is spending over 20 percent of its total turnover on R&D activities. CinnaGen is strategically positioned to become and remain leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products, through strategic partnerships to promote sustainable development in human health.


Industries

Employees

501-1,000

Links